Clinical

Dataset Information

0

BC001 Combined TAS-102 in a multicenter phase II clinical study in patients with metastatic colorectal cancer who have failed or not tolerated first-and second-line standard therapy


ABSTRACT: Interventions: Experimental group:BC001 combined with TAS-102 treatment Primary outcome(s): BC001 Safety of combined TAS-102 in patients with metastatic colorectal cancer who failed or tolerated first-line and second-line standard treatment, including: adverse events, blood routine, blood chemistry and urine routine, physical examination, vital signs and electrocardiogram results. Study Design: Single arm

DISEASE(S): Patients With Metastatic Colorectal Cancer Who Fail Or Do Not Tolerate First-line And Second-line Standard Therapy

PROVIDER: 86191 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2023-03-31 | GSE226221 | GEO
2024-08-26 | GSE275628 | GEO
| 110053 | ecrin-mdr-crc
| 2386605 | ecrin-mdr-crc
| 87000 | ecrin-mdr-crc
| 2717618 | ecrin-mdr-crc
| 114606 | ecrin-mdr-crc
| 14404 | ecrin-mdr-crc
| 92106 | ecrin-mdr-crc
| 113359 | ecrin-mdr-crc